【摘要】 目的探讨瑞舒伐他汀与阿托伐他汀对冠脉介入术后肾功能的影响。方法入选2012年1月至2012年12月在北京电力医院接受冠脉造影和(或)冠脉介入治疗患者100例,术前被随机分为2组,一组(瑞舒伐他汀组)术前开始服用瑞舒伐他汀10mg每晚1次,术后服用10mg每晚一次维持,共入组50例;另一组(阿托伐他汀组)术前开始服用阿托伐他汀20mg,术后服用20mg每晚一次维持,共入组50例,观察术后48小时的估算肾小球滤过率(estimated GFR)。结果 2组间比较,瑞舒伐他汀与阿托伐他汀对行介入后患者肾功能影响无明显差异,P>0.05。结论瑞舒伐他汀和阿托伐他汀均可提高肾小球滤过率,且两药对改善肾小球滤过率的作用没有显著差异,在eGFR>60ml/min/1.73m2患者中介入前使用瑞舒伐他汀与阿托伐他汀是安全、有效的,值得在临床推广应用。更多还原

【Abstract】 Objective To evaluate effects of rosuvastatin and atorvastatin on renal function in patients underwent coronary angiography or intervention.Methods From January 2012 to December 2012,A total of 100 patients underwent coronary angiography and/or percutaneous coronary interventions were randomized to the therapy with rosuvastatin group(n=50)and the therapy with atorvastatin group(n=50).In the rosuvastatin group,the patients received rosuvastatin tablets 10mg/day before and after intervention.In the atorvastatin group,the patients received atorvastatin tablets 20mg/day before and after intervention.Before and after the procedure,estimated GFR(eGFR)were compared between the two groups.Results eGFR was no significant difference between two g roups.Conclusion Both rosuvastatin and atorvastatin improve eGFR.Rosuvastatin and atorvastatin use before angiography is worth promoting and safe in the patients with eGFR>60ml/min/1.73m2.更多还原